"Glutathione reductase from germinated peas"
however, they differ in how they approach medications, personalization, and their care structures
This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway is trying to solve the problem
Oral semaglutide (NVO): ~15% in obesity at the highest dose in phase 3
These assays typically involve expressing the receptor in cell lines and measuring downstream signaling events, such as cyclic AMP production or calcium flux, when the test molecule is added